INXN-1001

DRUG2 trials

Sponsors

Alaunos Therapeutics

Conditions

Melanoma

Phase 1

Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

CompletedNCT00815607

Alaunos TherapeuticsMelanoma

Start: 2009-04-30End: 2013-01-31Updated: 2013-07-18

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

CompletedNCT01397708

Alaunos TherapeuticsMelanoma

Start: 2011-08-31End: 2014-09-30Updated: 2025-10-29